Latest Company News

• If You Invested $1,000 in Oncolytics Biotech Inc (ONCY)
  Stock Titan · Mar 22, 2026 neutral
  This article analyzes the historical performance of a $1,000 investment in Oncolytics Biotech Inc (ONCY) over various periods, showing significant fluctuations including a 51.0% gain over one year but substantial losses over five and ten years. It also provides an overview of Oncolytics Biotech, a clinical-stage biotechnology company developing pelareorep for cancer immunotherapy, highlighting its focus on gastrointestinal cancers, clinical trial progress, regulatory interactions, and intellectual property strategy. The company is pursuing pivotal studies in pancreatic, colorectal, and anal cancers, and is moving to align its corporate structure with its U.S.-focused operations.
• Oncolytics Biotech completes first step of redomestication to British Columbia
  Investing.com · Mar 21, 2026 neutral
  Oncolytics Biotech Inc. has completed the initial phase of its redomestication process, moving its incorporation from Alberta to British Columbia, Canada. The company's common shares, name, and trading symbol (ONCY) remain unchanged. A second phase is planned for March 31, 2026, to move incorporation to Nevada, USA, which will entail a change in CUSIP and ISIN numbers but no change to the company name or Nasdaq symbol.
• Form 8K Oncolytics Biotech Inc. For: 20 March
  Investing.com · Mar 20, 2026 neutral
  This article reports on Oncolytics Biotech Inc.'s Form 8K filing for March 20. It includes standard disclaimers about the risks inherent in financial and cryptocurrency trading, noting that information provided is not real-time or necessarily accurate and should not be relied upon for trading purposes. Fusion Media highlights that it is not liable for losses based on website information and reserves all intellectual property rights.
• Oncolytics Biotech (NASDAQ: ONCY) outlines move from Canada to Nevada
  Stock Titan · Mar 20, 2026 neutral
  Oncolytics Biotech has initiated a two-step redomestication process, first changing its incorporation jurisdiction from Alberta to British Columbia, Canada, and then planning to move to Nevada, USA, by March 31, 2026. This move keeps the company's name and Nasdaq ticker ONCY but will change its CUSIP and ISIN identifiers. The company's shareholders approved these changes, which will alter the governing corporate laws for the company.
• Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
  GlobeNewswire · Mar 19, 2026 somewhat-bullish
  Oncolytics Biotech announced that two abstracts on its immunotherapy pelareorep have been accepted for presentation at the AACR Annual Meeting 2026. The data highlight pelareorep's ability to activate immune responses, form tertiary lymphoid structures, and potentially enhance the efficacy of combination therapies in various cancers, including RAS-driven tumors and advanced pancreatic cancer. These findings support pelareorep's role as a foundational backbone for combination therapy, with promising biomarker data from the GOBLET trial and evidence of immune conversion activity.